Evidence map›Paper›PMID 31533757›Full record

ArticleRadiation oncology (London, England)2019

Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.

Jie Chen, Wenming Yin, Hui Yao, Wendong Gu

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2.Esophagus : official journal of the Japan Esophageal Society · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jie ChenDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, No. 185 Juqian Street, Changzhou, 213003, China.
Wenming YinDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, No. 185 Juqian Street, Changzhou, 213003, China.
Hui YaoDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, No. 185 Juqian Street, Changzhou, 213003, China.
Wendong GuDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, No. 185 Juqian Street, Changzhou, 213003, China. guwendong1415@czfph.com.ORCID http://orcid.org/0000-0001-6772-065X
Soochow University · CN

Funding

Chinese Society of Clinical Oncology Y-HR2018-063
6 · The paper itself

Abstract

backgroundPatients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients.

methodsThe survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4-66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP).

resultsThe median follow-up time was 24 (range, 9-75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5-75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred.

conclusionsThese results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.

Indexed as

Salvage TherapyAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyFemaleFluorouracilHumansLymph NodesMaleMiddle AgedNeoplasm Recurrence, LocalCisplatinFluorouracilPaclitaxelChemoradiotherapyEsophageal squamous cell carcinomaLymph node recurrenceRadical surgeryRadiotherapy

Identifiers

PMID31533757
PMCPMC6749665
OpenAlexW2974132749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.